Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Anti-myeloma activity of pamidronate in vivo.

Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B.

Br J Haematol. 1998 Nov;103(2):530-2.

PMID:
9827929
2.

Anti-tumor activity of pamidronate in human multiple myeloma.

Kondo H, Mori A.

Leuk Lymphoma. 2002 Apr;43(4):919-21.

PMID:
12153188
3.

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.

Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, Soutar RL, Rogers MJ.

Br J Haematol. 2002 Nov;119(2):475-83.

PMID:
12406088
4.
5.

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.

Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

6.

Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.

Kraj M, Pogłód R, Pawlikowski J, Maj S, Nasiłowska B.

Acta Pol Pharm. 2000 Nov;57 Suppl:113-6.

PMID:
11293237
7.

A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE.

Blood. 2001 Apr 15;97(8):2522-3. Review.

8.

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.

Terpos E, Palermos J, Viniou N, Vaiopoulos G, Meletis J, Yataganas X.

Calcif Tissue Int. 2001 May;68(5):285-90.

PMID:
11683535
9.

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F.

Blood. 1999 May 1;93(9):3064-73.

10.

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.

Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, Meletis J, Yataganas X.

Eur J Haematol. 2000 Nov;65(5):331-6.

PMID:
11092464
11.

Bone complications in multiple myeloma.

Berenson JR, Rajdev L, Broder M.

Cancer Biol Ther. 2006 Sep;5(9):1082-5. Epub 2006 Sep 20. Review.

PMID:
16969119
12.

Bisphosphonates for cancer patients: why, how, and when?

Body JJ, Mancini I.

Support Care Cancer. 2002 Jul;10(5):399-407. Epub 2001 Oct 19. Review.

PMID:
12136223
13.

Initial bone marrow findings in multiple myeloma. Significance of plasma cell nodules.

Buss DH, Prichard RW, Hartz JW, Cooper MR, Feigin GA.

Arch Pathol Lab Med. 1986 Jan;110(1):30-3.

PMID:
3753566
14.

[Plasmocytic pleural effusion disclosing multiple myeloma].

Elloumi M, Frikha M, Masmoudi H, Mseddi S, Ben Ayed M, Bouaziz M, Makni F, Souissi T.

Rev Mal Respir. 2000 Apr;17(2):495-7. French.

PMID:
10859769
15.

Discordant response or progression in patients with myeloma treated with thalidomide-based regimens.

Anagnostopoulos A, Hamilos G, Zorzou MP, Grigoraki V, Anagnostou D, Dimopoulos MA.

Leuk Lymphoma. 2004 Jan;45(1):113-6.

PMID:
15061206
16.

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ.

Blood. 2002 Nov 1;100(9):3095-100.

17.

[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].

Leng Y, Chen SL, Shi HZ.

Space Med Med Eng (Beijing). 2002 Oct;15(5):377-8. Chinese.

PMID:
12449148
18.

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J.

Br J Haematol. 2002 Feb;116(2):278-90.

PMID:
11841428
19.

Bisphosphonate therapy in multiple myeloma.

Laakso M, Jantunen E.

Acta Oncol. 1996;35 Suppl 5:55-6. Review.

PMID:
9142966
20.

Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.

Kumar S, Rajkumar SV, Greipp PR, Witzig TE.

Am J Hematol. 2004 Sep;77(1):7-11.

Supplemental Content

Support Center